患有COVID-19多发性髓瘤患者的临床特征和风险分层
Ruifang Zheng1, Kelsey Mieth2, Christen Bennett2
1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
多发性骨髓瘤患者面临严重的COVID-19结果,活性化疗增加了风险. 中和抗体降低了死亡率,建议在接种疫苗后进行抗体测试以更好地预防.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- 多发性骨髓瘤 (MM) 患者表现出对严重的COVID-19的敏感性增加.
- 了解临床特征和治疗影响对于管理SARS-CoV-2的MM患者至关重要.
研究的目的:
- 总结MM患者COVID-19的临床特征.
- 评估MM治疗对COVID-19结果的影响.
- 对预防策略的血清学反应进行审查.
主要方法:
- 对34名感染SARS-CoV-2的MM患者的回顾性分析 (2020年3月至2021年8月).
- 研究了化疗,巴姆拉尼维马布和达拉图穆马布对住院和死亡率的影响.
- 感染/接种疫苗后审查的血清反应.
主要成果:
- MM患者的COVID-19住院和死亡率较高,特别是那些接受活性化疗的患者.
- 高龄,高风险骨髓瘤,脏疾病和疾病控制不良预测了不良结果.
- 达拉图马布没有恶化结果或影响血清阳性; 中和抗体降低死亡率.
结论:
- 型MM患者,特别是那些接受化疗的患者,需要仔细管理COVID-19.
- 接种疫苗后的中和抗体测试可能对MM患者有益.
- 基于年龄,疾病状况和并发症的风险分层是必要的.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
相关概念视频
Myocarditis II: Clinical Features and Diagnostic Tests
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Cancer Survival Analysis
